AR116922A1 - Formulación basada en ciclodextrina de un inhibidor de bcl-2 - Google Patents

Formulación basada en ciclodextrina de un inhibidor de bcl-2

Info

Publication number
AR116922A1
AR116922A1 ARP190103144A ARP190103144A AR116922A1 AR 116922 A1 AR116922 A1 AR 116922A1 AR P190103144 A ARP190103144 A AR P190103144A AR P190103144 A ARP190103144 A AR P190103144A AR 116922 A1 AR116922 A1 AR 116922A1
Authority
AR
Argentina
Prior art keywords
cyclodextrin
pharmaceutical composition
bcl
inhibitor
dimethyl
Prior art date
Application number
ARP190103144A
Other languages
English (en)
Inventor
Maa Chanrion
Jean Pean
- Tran Thu Thuy Manuel
Caroline Chemin
Original Assignee
Servier Lab
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab, Novartis Ag filed Critical Servier Lab
Publication of AR116922A1 publication Critical patent/AR116922A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente se refiere a una composición farmacéutica que comprende 5-(5-cloro-2-{[(3S)-3-(morfolin-4-ilmetil)-3,4-dihidroisoquinolin-2(1H)-il]carbonil}fenil)-N-(5-ciano-1,2-dimetil-1H-pirrol-3-il)-N-(4-hidroxifenil)-1,2-dimetil-1H-pirrol-3-carboxamida, referida en la presente memoria como ‘Compuesto A’, o una sal farmacéuticamente aceptable de la misma, y una ciclodextrina. Más específicamente, la presente se refiere a una composición farmacéutica sólida que comprende el Compuesto A y una ciclodextrina, y una composición farmacéutica para administración parenteral preparada disolviendo esta composición farmacéutica sólida. Además, la presente se refiere al uso de dichas composiciones para el tratamiento del cáncer.
ARP190103144A 2018-10-31 2019-10-30 Formulación basada en ciclodextrina de un inhibidor de bcl-2 AR116922A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862753164P 2018-10-31 2018-10-31

Publications (1)

Publication Number Publication Date
AR116922A1 true AR116922A1 (es) 2021-06-30

Family

ID=68536777

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP190103144A AR116922A1 (es) 2018-10-31 2019-10-30 Formulación basada en ciclodextrina de un inhibidor de bcl-2

Country Status (25)

Country Link
US (1) US20210353633A1 (es)
EP (1) EP3873529A1 (es)
JP (1) JP2022506069A (es)
KR (1) KR20210102886A (es)
CN (1) CN112912108A (es)
AR (1) AR116922A1 (es)
AU (1) AU2019373373B2 (es)
BR (1) BR112021007987A2 (es)
CA (1) CA3117511A1 (es)
CL (1) CL2021001018A1 (es)
CO (1) CO2021005221A2 (es)
CR (1) CR20210210A (es)
DO (1) DOP2021000073A (es)
EA (1) EA202191144A1 (es)
GE (1) GEP20237580B (es)
IL (1) IL282688A (es)
JO (1) JOP20210079A1 (es)
MX (1) MX2021004864A (es)
NI (1) NI202100031A (es)
PE (1) PE20211738A1 (es)
PH (1) PH12021550878A1 (es)
SG (1) SG11202103965TA (es)
TW (1) TWI738100B (es)
UY (1) UY38431A (es)
WO (1) WO2020089286A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4188387A1 (en) 2020-07-31 2023-06-07 Les Laboratoires Servier Combination of a bcl-2 inhibitor and a hypomethylating agent for treating cancers, uses and pharmaceutical compositions thereof
WO2022090443A1 (en) 2020-10-30 2022-05-05 Les Laboratoires Servier Administration and dose regimen for a combination of a bcl-2 inhibitor and a mcl1 inhibitor
JP2024511422A (ja) 2021-03-24 2024-03-13 レ ラボラトワール セルヴィエ ５－｛５－クロロ－２－［（３ｓ）－３－［（モルホリン－４－イル）メチル］－３，４－ジヒドロイソキノリン－２（１ｈ）－カルボニル］フェニル｝－１，２－ジメチル－１ｈ－ピロール－３－カルボン酸誘導体を合成するための新規な製造方法及び医薬化合物を製造するためのその適用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996041646A2 (en) * 1995-06-13 1996-12-27 Dyer, Alison, Margaret Pharmaceutical compositions containing lornoxicam and cyclodextrin
JP2003321364A (ja) * 2002-05-07 2003-11-11 Eisai Co Ltd シクロデキストリンにより可溶化及び安定化された抗腫瘍剤含有組成物
WO2014108918A2 (en) * 2013-01-08 2014-07-17 Mylan Laboratories Limited An injectable antifungal formulation
FR3008975A1 (fr) * 2013-07-23 2015-01-30 Servier Lab Nouveaux derives de pyrrole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US20200054639A1 (en) * 2016-10-31 2020-02-20 Oregon Health & Science University Combinations of agents to treat hematological malignancies

Also Published As

Publication number Publication date
EP3873529A1 (en) 2021-09-08
TW202031295A (zh) 2020-09-01
CA3117511A1 (en) 2020-05-07
PH12021550878A1 (en) 2021-10-18
AU2019373373A1 (en) 2021-05-20
WO2020089286A1 (en) 2020-05-07
KR20210102886A (ko) 2021-08-20
CO2021005221A2 (es) 2021-07-19
CR20210210A (es) 2021-05-25
CL2021001018A1 (es) 2021-11-26
BR112021007987A2 (pt) 2021-08-03
MX2021004864A (es) 2021-08-11
JOP20210079A1 (ar) 2023-01-30
US20210353633A1 (en) 2021-11-18
JP2022506069A (ja) 2022-01-17
GEP20237580B (en) 2023-12-25
UY38431A (es) 2020-05-29
NI202100031A (es) 2021-08-24
TWI738100B (zh) 2021-09-01
AU2019373373B2 (en) 2023-09-28
PE20211738A1 (es) 2021-09-06
SG11202103965TA (en) 2021-05-28
IL282688A (en) 2021-06-30
DOP2021000073A (es) 2021-11-15
CN112912108A (zh) 2021-06-04
EA202191144A1 (ru) 2021-09-27

Similar Documents

Publication Publication Date Title
NI202100031A (es) Formulación basada en ciclodextrina de un inhibidor de bcl-2
BR112016011949A2 (pt) Composto, composição farmacêutica, e, uso dos mesmos”
DOP2018000273A (es) Compuestos químicos
UY30819A1 (es) Derivados de pirazol, composiciones farmacéuticas conteniéndolos, procesos de preparacion y aplicaciones
AR090349A1 (es) Terapia de combinacion para trastornos proliferativos, kit y uso
BR112015029512A2 (pt) derivados de pirazolopirrolidina e seu uso no tratamento de doenças
HUP0303271A2 (hu) Rapamycin felhasználása rák kezelésére alkalmas gyógyszerkészítmény elõállítására
WO2008004798A8 (en) Compounds that inhibit hif-1 activity, the method for preparation thereof and the pharmaceutical composition containing them as an effective component
RU2013121788A (ru) Ингибиторы репликации вич
EA201170527A1 (ru) Фармацевтические композиции, включающие соединения бороновой кислоты
BR112020006381A8 (pt) Composto, composição farmacêutica, e, uso de um composto ou de uma composição farmacêutica
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
AR085662A1 (es) Metodos y composiciones para tratar la hiperuricemia y trastornos metabolicos asociados con la hiperuricemia
BRPI0906444A8 (pt) compostos de 4-piridinona e seu uso para câncer
CL2021001629A1 (es) Compuestos de halo-alilamina y uso de los mismos
BRPI0816798A2 (pt) composto, composição farmacêutica, métodos para inibir a ação do glicogênio sintase cinase-3, e para tratar, prevenir ou melhorar uma doença, uso de um composto, e, artigo de fabricação
BR112022002392A2 (pt) Formas em estado sólido de (s)-2-(((s)-6,8-difluoro-1,2,3,4-tetra-hidronaftalen-2-il)amino)-n-(1-(2-metil-1)-(neopentilamino)propan-2-il)-1h-imidazol-4-il)pentanamida e seus usos
AR064543A1 (es) Uso de derivados de mononitrato de dianhidrohexita como agentes para el tratamiento de trastornos intestinales
BRPI0418742A (pt) métodos de tratamento, prevenção ou controle de uma sìndrome mielodisplásica, de redução ou evitação de um efeito adverso associado com a administração de um segundo ingrediente ativo em um paciente sofrendo de um sìndrome mielodisplásica, composição farmacêutica, forma de dosagem unitária única, e, kit
CO2019004004A2 (es) Composición farmacéutica y método para el tratamiento de la enfermedad del hígado graso no alcohólico
CL2009001267A1 (es) Compuestos derivados de triciclos nitrogenados, con actividad antibacteriana; procedimiento de preparacion; composicion farmceutica que los comprende; para el tratamiento de la tuberculosis.
JP2018506533A5 (es)
FR3056108A1 (fr) Utilisation des harringtonines dans le traitement cancer du sein, notamment triple-negatif
BRPI0418743A (pt) métodos de tratamento, prevenção ou controle de uma sìndrome mielodisplásica, de redução ou evitação de um efeito adverso associado com a administração de um segundo ingrediente ativo em um paciente sofrendo de uma sìndrome mielodisplásica, composição farmacêutica, forma de dosagem unitária única, e, kit
BR112018017005A2 (pt) composto derivado de entecavir e composição farmacêutica para prevenir ou tratar hepatite b